Bin-chi Liao
Hsin Chu Branch
Hsinchu, TNQ, Taiwan
Hsinchu, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: January 17, 2026
Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: January 17, 2026
PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC.
Journal: Journal of biomedical science
Published: July 30, 2025
Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521.
Journal: JCO global oncology
Published: September 30, 2024
Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.
Journal: Clinical and translational medicine
Published: September 22, 2024
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE).
Journal: JTO clinical and research reports
Published: September 18, 2024
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: May 05, 2024
A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
Journal: Cancers
Published: August 10, 2023
Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Journal: Oncology
Published: July 04, 2023
Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis.
Journal: BMC cancer
Published: October 02, 2022
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma.
Journal: Nature communications
Published: July 15, 2022
Last Updated: 09/26/2026